ALZN - CIK 0001677077
The table below shows Alzamend Neuro, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.71M | $4.45M | $5.62M | $3.36M | $4.09M | $1.19M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.70M |
| $4.72M |
| $5.93M |
| $3.95M |
| $4.77M |
| $1.42M |
| Property, plant & equipment | $342.55K | $370.24K | $397.92K | $228.29K | $240.98K | $253.66K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $4.04M | $5.09M | $6.33M | $4.18M | $5.01M | $1.67M |
| Accounts payable | - | - | - | $725.85K | $1.25M | $2.88M |
| Total current liabilities | - | - | - | $3.83M | - | - |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.86M | $717.49K | $983.31K | $725.85K | $1.25M | $2.88M |
| Retained earnings | -$64.44M | -$62.24M | -$61.24M | -$57.40M | -$56.41M | -$54.99M |
| Total equity | $2.18M | $4.37M | $5.34M | $3.45M | $3.75M | -$1.21M |